Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

By T. Haque, G. Wilkie, Marie M. Jones, C. Higgins, G. Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, C. Bellamy and 6 more. Blood, 2007

645 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EBV Positive Mucocutaneous Ulcer – A study of 26 cases associated with various sources of immunosuppression (2010, background): “The overall outcomes of EBVMCU highlight an indolent and self-limited condition, arguing for a conservative therapeutic approach, possibly including rituximab therapy or agents capable of enhancing immunologic control over EBV.11,19,20 The incidence of EBVMCU is difficult to establish with certainty”
Immunobiology of Human Cytomegalovirus: from Bench to Bedside (2009, methodology): “Another alternative strategy to reduce the time scale for the production of T cells is to use HLA-matched allogeneic virus-specific T cells (99, 161).”